As consumers taking medications like Ozempic cut back on eating out, about 70% are spending more on cooking at home, ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

June could provide an opportunity for investors according to Evercore ISI with the Fed expected to lower interest rates and ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...